The company owns technologies and proprietary drug delivery platforms.

Its lead candidate, DUR-928 for chronic liver diseases, acute organ injury and inflammatory disorders, is in Phase II development.

In July 2019, the company entered a license agreement with Gilead Sciences, for a long-acting injectable HIV investigational product.

Founded in 1998, the company is based in the USA.